 |
Disease
Areas of Focus
 HIV/AIDS
An
estimated 38.6 million people worldwide were living with HIV
at the end of 2005. In the same year, an estimated 4.1 million
became newly infected with HIV, and an estimated 2.8 million
lost their lives
to AIDS.1
Although
recent major advances in HIV/AIDS drug therapies have substantially
improved life expectancy and quality of life for many of those
receiving treatment, the AIDS epidemic continues to claim many
lives around the world. Moreover, of those patients receiving
treatment, substantial numbers do not respond well. Thus, Bristol-Myers
Squibb
is devoting substantial scientific and financial resources to
discovering and developing new HIV/AIDS drugs to complement products
it has
already provided. In addition, Bristol-Myers Squibb’s SECURE
THE FUTURE® program
continues to play a leadership role in combating HIV/AIDS in
that part of the world hardest hit by the
epidemic—southern and west Africa.
Back
to Disease Areas
1. “2006 Report on the Global AIDS Epidemic,” Joint
United Nations Program on HIV/AIDS |
